Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae-Reference-Cited by-同舟云学术

Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

Published:2019-02 Issue:2 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Abodakpi Henrietta¹,Chang Kai-Tai²,Gao Song¹,Sánchez-Díaz Ana María³,Cantón Rafael³,Tam Vincent H.¹²

Affiliation:

1. Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, Texas, USA

2. Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA

3. Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

Abstract

Piperacillin-tazobactam has been proposed as an alternative to carbapenems for the treatment of infections caused by extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae . However, limited understanding of optimal dosing strategies for this combination may curtail its utility.

Funder

European Commission

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01906-18

Reference25 articles.

1. Resistance in Gram-Negative Bacteria: Enterobacteriaceae

2. Carbapenem resistance in Enterobacteriaceae: here is the storm!

3. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?